A detailed history of Citigroup Inc transactions in Pep Gen Inc. stock. As of the latest transaction made, Citigroup Inc holds 3,399 shares of PEPG stock, worth $29,911. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,399
Previous 40,610 91.63%
Holding current value
$29,911
Previous $596,000 90.94%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$10.54 - $18.14 $392,203 - $675,007
-37,211 Reduced 91.63%
3,399 $54,000
Q1 2024

May 10, 2024

BUY
$6.63 - $17.3 $260,161 - $678,852
39,240 Added 2864.23%
40,610 $596,000
Q4 2023

Feb 09, 2024

BUY
$3.86 - $7.96 $4,126 - $8,509
1,069 Added 355.15%
1,370 $9,000
Q3 2023

Nov 09, 2023

SELL
$5.0 - $9.09 $215,735 - $392,206
-43,147 Reduced 99.31%
301 $1,000
Q2 2023

Aug 10, 2023

BUY
$8.94 - $16.39 $386,002 - $707,671
43,177 Added 15932.47%
43,448 $388,000
Q1 2023

May 11, 2023

SELL
$11.44 - $17.7 $1,567 - $2,424
-137 Reduced 33.58%
271 $3,000
Q4 2022

Feb 09, 2023

BUY
$9.31 - $16.57 $2,439 - $4,341
262 Added 179.45%
408 $5,000
Q3 2022

Nov 10, 2022

SELL
$4.86 - $12.75 $1,978 - $5,189
-407 Reduced 73.6%
146 $1,000
Q2 2022

Aug 10, 2022

BUY
$9.0 - $12.89 $4,977 - $7,128
553 New
553 $5,000

Others Institutions Holding PEPG

About PepGen Inc.


  • Ticker PEPG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,631,900
  • Market Cap $208M
  • Description
  • PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is a...
More about PEPG
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.